Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.

Journal of thrombosis and haemostasis : JTH - 1 May 2010

Pérez-Andreu V, Roldán V, López-Fernández M F, Antón A I, Alberca I, Corral J, Montes R, García-Barberá N, Ferrando F, Vicente V, González-Conejero R

Abstract excerpt

SUMMARY BACKGROUND: There is currently intense debate as to whether pharmacogenetic algorithms for estimating the initial dose of coumarins provide a more accurate dose than the fixed-dose approach. Recently, it has been suggested that the greatest benefit of pharmacogenetic algorithms is observe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acenocoumarol
Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Cytochrome P-450 Enzyme System

Share to Cytochrome P450 Family 4

Share to Mixed Function Oxygenases

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 20149073
DOI: 10.1111/j.1538-7836.2010.03800.x

Genes

VKORC1
CALU
GGCX

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20149073-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.PMID 20149073Read ↗

CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.Semantic proximity Read ↗

A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants.Semantic proximity Read ↗

Creating a genotype-based dosing algorithm for acenocoumarol steady dose.Semantic proximity Read ↗

Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.Semantic proximity Read ↗

Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirementsSemantic proximity Read ↗

Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.Semantic proximity Read ↗

Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis.Semantic proximity Read ↗

The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population.Semantic proximity Read ↗

Acenocoumarol Pharmacogenetic Dosing Algorithms and Their Application in Two Bulgarian Patients with Low Anticoagulant Requirements.Semantic proximity Read ↗

Novel associations of VKORC1 variants with higher acenocoumarol requirements.Semantic proximity Read ↗

Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.Semantic proximity Read ↗

Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.